.jpg)
Today in the U.S., more than five million people are living with mild-to-moderate Alzheimer’s disease (AD). As we live longer, rates of AD have grown dramatically and the disease is now cited as the third leading cause of death in the United States. Alzheimer’s disease affects more than five million individuals in the United States and is now the third leading cause of death in the U.S.
At The Mount Sinai Medical Center Wien Center for Alzheimer’s Disease and Memory Disorders, national and international research and clinical trials for Alzheimer’s treatment and prevention are underway. The Wien Center is the lead institution for the Florida Brain Bank, which helps researchers gain a better understanding of Alzheimer’s and other memory disorders and provides resources for researchers around the globe to study the disease.
Encouraging strides are being made toward early intervention and preventative therapies in AD. However, at the same time, AD clinical researchers cannot – and will not – leave anyone behind as the research progresses. We are well aware that new therapies are desperately needed for people currently diagnosed with AD.
Alzheimer’s disease, the most common type of dementia, develops when nerve cells in the brain no longer function normally, causing a decline in memory, other cognitive functions and ability to function normally. Mild-to-moderate AD signals the stage at which the decline in cognitive function becomes apparent to friends and family. Symptoms of mild-to-moderate AD include everything from increased difficulty performing simple tasks such as paying bills, to forgetfulness about one’s own personal history and becoming moody and withdrawn in social situations. For those who have ever loved or cared for someone with AD, it becomes apparent that caring for an AD patient often becomes a full time job, impacting quality of life not only for the patient but for the caregiver as well. For caregivers, the gradual but permanent decline in their loved one’s mental and physical capabilities often takes a deep emotional and psychological toll.
Researchers at Mount Sinai are committed to providing patients with access to studies that will help advance research on Alzheimer’s at all stages of the disease. To push this initiative forward, Mount Sinai is currently participating in the NOBLE Study, a clinical trial of an investigational medication that uses a neuroprotectant approach that has been used successful in many central nervous system disorders including stroke and Parkinson’s disease. The study will focus on evaluating a medication specifically for those with mild-to-moderate AD.
The NOBLE study is one example of ways patients and their families can play a critical role in helping researchers find new treatment approaches to improve the lives of those impacted by Alzheimer’s disease, and we look forward to engaging members of the South Florida community who may be interested in participating.
NOBLE is a Phase-2 multi-center, randomized, double blind, placebo-controlled, parallel group study. The duration of treatment is about 14 months.
Participants will be screened for eligibility and must be:
• Aged 55-85 years old with mild to moderate Alzheimer’s Disease
• Receiving donepezil (Aricept®) treatment for at least 6 months
• Living in the community (not a nursing home)
• Have a study partner that has regular contact and who will attend study visits
• Weigh no more than 220 pounds
